DE602006014009D1 - Nukleinsäure konstrukten, pharmazeutische kompositionen und methoden für die behandlung von krebs - Google Patents

Nukleinsäure konstrukten, pharmazeutische kompositionen und methoden für die behandlung von krebs

Info

Publication number
DE602006014009D1
DE602006014009D1 DE602006014009T DE602006014009T DE602006014009D1 DE 602006014009 D1 DE602006014009 D1 DE 602006014009D1 DE 602006014009 T DE602006014009 T DE 602006014009T DE 602006014009 T DE602006014009 T DE 602006014009T DE 602006014009 D1 DE602006014009 D1 DE 602006014009D1
Authority
DE
Germany
Prior art keywords
nucleic acid
methods
cancer
treatment
pharmaceutical compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602006014009T
Other languages
English (en)
Inventor
Avraham Hochberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yissum Research Development Co of Hebrew University of Jerusalem
Original Assignee
Yissum Research Development Co of Hebrew University of Jerusalem
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Research Development Co of Hebrew University of Jerusalem filed Critical Yissum Research Development Co of Hebrew University of Jerusalem
Publication of DE602006014009D1 publication Critical patent/DE602006014009D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
DE602006014009T 2005-09-22 2006-09-21 Nukleinsäure konstrukten, pharmazeutische kompositionen und methoden für die behandlung von krebs Active DE602006014009D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71917805P 2005-09-22 2005-09-22
PCT/IL2006/001110 WO2007034487A1 (en) 2005-09-22 2006-09-21 Nucleic acid constructs, pharmaceutical compositions and methods of using same for treating cancer

Publications (1)

Publication Number Publication Date
DE602006014009D1 true DE602006014009D1 (de) 2010-06-10

Family

ID=37575053

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602006014009T Active DE602006014009D1 (de) 2005-09-22 2006-09-21 Nukleinsäure konstrukten, pharmazeutische kompositionen und methoden für die behandlung von krebs

Country Status (6)

Country Link
US (1) US8034914B2 (de)
EP (1) EP1926814B1 (de)
JP (1) JP2009508516A (de)
AT (1) ATE466079T1 (de)
DE (1) DE602006014009D1 (de)
WO (1) WO2007034487A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101273130B (zh) 2005-07-07 2012-05-30 耶路撒冷希伯来大学伊森姆研究发展公司 用于下调h19的核酸物质及其使用方法
AU2008315409B2 (en) 2007-10-25 2013-10-31 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Constructs containing multiple expression cassettes for cancer therapy
US8492133B2 (en) 2009-01-20 2013-07-23 Ramot At Tel Aviv University, Ltd. MIR-21 promoter driven targeted cancer therapy
CN104797261A (zh) * 2012-04-10 2015-07-22 新加坡科技研究局 使用杆状病毒载体的膀胱癌治疗方法
US9701985B2 (en) 2013-06-04 2017-07-11 Virginia Commonwealth University mda-9/syntenin promoter to image and treat metastatic cancer cells
WO2014209553A1 (en) 2013-06-04 2014-12-31 Virginia Commonwealth University Use of a truncated ccn1 promoter for cancer diagnostics, therapeutics and theranostics
EP3004357A4 (de) 2013-06-04 2017-01-11 The Johns Hopkins University Peg-prom-vermittelte oberflächenexpression von avidin/streptavidin
WO2014197535A1 (en) 2013-06-04 2014-12-11 Virginia Commonwealth University Recombinant cancer therapeutic cytokine
EP3003393A4 (de) 2013-06-04 2017-01-11 The Johns Hopkins University Dreiteilige theranostische krebs-nukleinsäurekonstrukte
US9790488B2 (en) * 2013-08-02 2017-10-17 Agency For Science, Technology And Research Mutated internal ribosomal entry site (IRES) for controlled gene expression
SG10201909209RA (en) 2015-05-05 2019-11-28 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Nucleic acid-cationic polymer compositions and methods of making and using the same

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
US5830686A (en) 1994-01-13 1998-11-03 Calydon Tissue-specific enhancer active in prostate
IL108879A (en) 1994-03-07 2000-08-31 Yissum Res Dev Co Diagnostic assay for malignancies using the H19 gene and kit
US6087164A (en) 1997-10-03 2000-07-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Methods and compositions for inducing tumor-specific cytotoxicity
US20040009146A1 (en) * 2002-02-26 2004-01-15 Osvaldo Podhajcer Anti-tumor vaccine and method
WO2004024957A2 (en) 2002-09-12 2004-03-25 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method for detection of micro-metastasis

Also Published As

Publication number Publication date
WO2007034487A1 (en) 2007-03-29
WO2007034487A8 (en) 2007-07-05
EP1926814B1 (de) 2010-04-28
EP1926814A1 (de) 2008-06-04
US20090221681A1 (en) 2009-09-03
US8034914B2 (en) 2011-10-11
JP2009508516A (ja) 2009-03-05
WO2007034487B1 (en) 2007-08-23
ATE466079T1 (de) 2010-05-15

Similar Documents

Publication Publication Date Title
ATE466079T1 (de) Nukleinsäure konstrukten, pharmazeutische kompositionen und methoden für die behandlung von krebs
CL2021002241A1 (es) Proteínas de unión condicionalmente activadas restringidas (divisional de la solicitud no. 202000570)
CY1123400T1 (el) Ανθρωπινα anti-il-23 αντισωματα, συνθεσεις, μεθοδοι και χρησεις
CY1119454T1 (el) Αντισωματα εναντι cd38 για τη θεραπεια του πολλαπλου μυελωματος
ATE424159T1 (de) Katheter
CY1121580T1 (el) ΝΕΟΙ ΠΡΟΑΓΩΓΕΙΣ β-ΑΚΤΙΝΗΣ ΚΑΙ RPS21 ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΩΝ
DK1553975T3 (da) Optimerede Fc-varianter og fremgangsmåder til generering heraf.
BRPI0513310A (pt) análogos de tetrapeptìdeo
BRPI0616630B8 (pt) compostos de pirazol substituídos
NO20090047L (no) Anti-DLL4-antistoffer og fremgangsmater for anvendelse av disse
TW200738270A (en) Method of treating depression using a TNFα antibody
NO20091976L (no) Nye forbindelser
SG170802A1 (en) Systems and devices for sequence by synthesis analysis
ATE438638T1 (de) Sulfoniumsalze als photoinitiatoren für strahlungshärtbare systeme
WO2003104425A3 (en) NEW STABLE ANTI-CD22 ANTIBODIES
ATE414535T1 (de) Trägerproteine für impfstoffe
WO2008108830A8 (en) Immunogenic and therapeutic compositions for streptococcus pyogenes
AR069821A1 (es) Composiciones y metodos de uso de la interferencia de arn para el control de nematodos
NO20044564L (no) Fremgangsmater for behandling av nekrotiserende enterocolit
HUP0402656A2 (hu) Sejtterápiás eljárás tumorok kezelésére
MX2022005330A (es) Moleculas de union multiespecificas con scfv en el extremo nterminal.
GT200300046A (es) Indolil-urea derivados de tienopiridinas utiles como agentes antiangiogenicos y procedimientos para su uso
DE60109430D1 (de) An entzündlichen darmerkrankungen beteiligte gene und deren verwendung
BR112022012731A2 (pt) Anticorpo anti-ox40 e uso do mesmo
MY145888A (en) Hydrocarbon conversion process including a staggered-bypass reaction system

Legal Events

Date Code Title Description
8364 No opposition during term of opposition